Clinical Trial: Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis
Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional
Official Title: Palifermin Treatment of Toxic Epidermal Necrolysis
Brief Summary: To test the ability of palifermin (a recombinant human keratinocyte growth factor) to decrease mucocutaneous injury and to promote epithelial repair in Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis Overlap, diseases in which there is extensive sloughing of the skin and mucosa, including that of the eyes, gastrointestinal tract, respiratory and genitourinary systems.
Detailed Summary:
Sponsor: Brett King
Current Primary Outcome: Time-to-cutaneous Re-epithelialization [ Time Frame: The number of days between the start of palifermin administration and complete re-epithelialization of skin up to 14 days ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Time-to-mucosal Re-epithelialization [ Time Frame: The number of days between the start of palifermin administration and complete re-epithelialization of oral mucosa up to 14 days ]
- Time-to-cessation of Epidermal Necrosis [ Time Frame: The number of days between the start of palifermin administration and cessation of further epidermal necrosis up to 14 days ]
Original Secondary Outcome: Same as current
Information By: Yale University
Dates:
Date Received: January 13, 2014
Date Started: October 2010
Date Completion:
Last Updated: October 6, 2016
Last Verified: October 2016
